NCT00006417 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Kamani N, August CS, Campbell DE, Hassan NF, Douglas SD
Marrow transplantation in chronic granulomatous disease: an update, with 6-year follow-up. J Pediatr. 1988 Oct;113(4):697-700.
Kamani N, August CS, Douglas SD, Burkey E, Etzioni A, Lischner HW
Bone marrow transplantation in chronic granulomatous disease. J Pediatr. 1984 Jul;105(1):42-6.
Rappeport JM, Newburger PE, Goldblum RM, Goldman AS, Nathan DG, Parkman R
Allogeneic bone marrow transplantation for chronic granulomatous disease. J Pediatr. 1982 Dec;101(6):952-5.

HLA-Matched, Peripheral Blood Stem Cell Transplantation Using Low Intensity Conditioning to Treat Patients With Chronic Granulomatous Disease Who Are Actively Infected

Details for clinical trial NCT00006417

Clinical trial NCT00006417 - References